The MolecuLight i:X
is FDA cleared
to produce fluorescence imaging in skin wounds that, “when used in combination with clinical signs and symptoms, has been shown to increase the likelihood that clinicians can identify wounds containing bacterial loads >104
CFU per gram as compared to examination of clinical signs and symptoms alone.” This increased ability to detect elevated bacterial loads may improve clinical decision making about wound care. The following is a worldwide bibliography of representative published research papers investigating or evaluating the impact of the MolecuLight i:X
’s imaging on clinical decision making. Some of the papers explore uses of the i:X
outside the FDA clearance just quoted. None of the papers has been evaluated by the FDA. In some cases, MolecuLight provided devices or financial support for the research and/or MolecuLight employees participated.